本帖最后由 老马 于 2012-1-13 21:20 编辑
- `! C4 H4 a6 n9 g6 V( P' D5 h% U
爱必妥和阿瓦斯丁的比较9 Z0 A; H" i: t
" V3 W1 s f" {4 a( V4 s
http://cancergrace.org/lung/2008/08/30/bms099-os-neg/, J$ X7 Q0 P% {; v9 E9 y% U
- ]' K: [% W) d
, p- _4 w9 ]" Z8 s+ l; J _7 i6 Hhttp://cancergrace.org/lung/2007/12/27/platgem-erbitux-trial/
' N! Q1 _- a9 R& K# L==================================================1 p& l3 m" e' M' @2 r% i8 O# g
Overall survival with cisplatin–gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL)
* y) M7 ~: h3 k) `" O) hPatients and methods: Patients (n = 1043) received cisplatin 80 mg/m2 and gemcitabine 1250 mg/m2 for up to six cycles plus bevacizumab 7.5 mg/kg (n = 345), bevacizumab 15 mg/kg (n = 351) or placebo (n = 347) every 3 weeks until progression. Primary end point was progression-free survival (PFS); OS was a secondary end point.3 {5 Q* n( Z! I! J* h# n' p
Results: Significant PFS prolongation with bevacizumab compared with placebo was maintained with longer follow-up {hazard ratio (HR) [95% confidence interval (CI)] 0.75 (0.64–0.87), P = 0.0003 and 0.85 (0.73–1.00), P = 0.0456} for the 7.5 and 15 mg/kg groups, respectively. Median OS was >13 months in all treatment groups; nevertheless, OS was not significantly increased with bevacizumab [HR (95% CI) 0.93 (0.78–1.11), P = 0.420 and 1.03 (0.86–1.23), P = 0.761] for the 7.5 and 15 mg/kg groups, respectively, versus placebo. Most patients (~62%) received multiple lines of poststudy treatment. Updated safety results are consistent with those previously reported.* e* b. `9 F5 H+ P; U7 [ |
|